Resolution of persistent cystoid macular edema due to central retinal vein occlusion in a vitrectomized eye following intravitreal implant of dexamethasone 0.7 mg

Case Reports in Ophthalmology

Volumn 3, Issue 1, 2012, Pages 30-34

  Reibaldi, Michele ^a   Russo, Andrea ^a   Zagari, Marco ^a   Toro, Mario ^a   De Grande, Vittorio ^a   Cifalinò, Valentina ^a   Rametta, Stefania ^a   Faro, Salvatore ^a   Longo, Antonio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Central retinal vein occlusion; Cystoid macular edema; Dexamethasone 0.7 mg; Ozurdex ; Vitrectomized eye

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE;

ADULT; ARTICLE; CASE REPORT; CENTRAL RETINA VEIN OCCLUSION; CLINICAL FEATURE; FEMALE; HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT RESPONSE; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 84860741348     PISSN: None     EISSN: 16632699     Source Type: Journal    
DOI: 10.1159/000336273     Document Type: Article

References (10)

1. Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM: Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 1996;103:551-560.
2. Ota M, Tsujikawa A, Ojima Y, Miyamoto K, Murakami T, Ogino K, Akagi-Kurashige Y, Muraoka Y, Yoshimura N: Retinal sensitivity after resolution of the macular edema associated with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol DOI: 10.1007/s00417-011-1860-0.
3. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.e3.
4. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.
5. Chang-Lin JE, Burke JA, Peng Q, Lin T, Orilla WC, Ghosn CR, Zhang KM, Kuppermann BD, Robinson MR, Whitcup SM, Welty DF: Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest Ophthalmol Vis Sci 2011;52:4605-4609.
6. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF: Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 2007;144:124-126.
7. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY, Liu CC, Lou J, Whitcup SM; Ozurdex CHAMPLAIN Study Group: Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31:915-923.
8. Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A: Müller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol 2007;45:627-636.
9. Meyer LM, Schönfeld CL: Fast resolution of recurrent pronounced macular edema following intravitreal injection of dexamethasone 0.7 mg. Case Rep Ophthalmol 2011;2:246-250.
10. Stefánsson E: Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol 2009;247:147-163.